EXERCISE METABOLISM & OXYGEN DELIVERY IN CHRONIC RENAL FAILURE

促红细胞生成素（EPO）已被证明是有效的治疗 慢性肾功能衰竭（CRF）的病因是什么？ 尽管此类 治疗确实改善了生活质量， EPO治疗并没有像人们预测的那样改善， 血红蛋白浓度增加。 我们预测尿毒症患者 肌病引起胞质功能障碍， 线粒体氧化能力 为了验证这一假设，我们测试了 六名CRF患者和六名相匹配的久坐不动的正常人， 巴塞罗那大学。 我们没有发现线粒体差异 在两组之间的差异。 然而，来自毛细血管的氧梯度 CRF组肌细胞氧摄取峰值高于对照组， 减少了。 此外，跨毛细血管梯度和氧摄取 CRF组呼吸100%氧气的水平相当于 正常组21%氧气（室内空气）。 研究结果表明， 在CRF患者中观察到的肌无力是由于氧气受损 输送系统，可能是由于毛细血管变性 网络 我们目前正在对活检组织进行形态测量学研究。 来证实这些发现

Erythropoietin (EPO) has proven to be effective in the treatment of anemia caused by chronic renal failure (CRF). Though such treatment does improve the quality of life, peak oxygen uptake after EPO therapy does not improve as much as one would predict given the increase in hemoglobin concentration. We predicted that uremic myopathy provokes a cytosolic dysfunction without altering mitochondrial oxidative capacity. To test this hypothesis, we tested six CRF patients and six matched sedentary normals here and at the University of Barcelona. We found no mitochondrial differences between the two groups. However, the oxygen gradients from capillary to muscle cell were higher in the CRF group, while peak oxygen uptake was reduced. Moreover, the transcapillary gradient and oxygen uptake levels for the CRF group breathing 100% oxygen were equivalent to the normals group at 21% oxygen (room air). The findings suggest that the muscle weakness observed in CRF patients is due to an impaired oxygen delivery system, probably as a result of degeneration in the capillary network. We are currently performing morphometry studies on biopsied samples from these subjects to corroborate these findings.